Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ACER

Acer Therapeutics (ACER)

Acer Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ACER
DateTimeSourceHeadlineSymbolCompany
11/14/20225:40PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
11/14/20225:38PMEdgar (US Regulatory)Amended Quarterly Report (10-q/a)NASDAQ:ACERAcer Therapeutics Inc
11/14/20225:29PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
11/14/20225:08PMGlobeNewswire Inc.Acer Therapeutics Reports Q3 2022 Financial Results and Provides Corporate UpdateNASDAQ:ACERAcer Therapeutics Inc
10/26/20229:02AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
10/26/20228:30AMGlobeNewswire Inc.Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO™ (celiprolol)NASDAQ:ACERAcer Therapeutics Inc
10/18/20224:05PMPR Newswire (US)SWK Holdings Provides Portfolio Update Highlighting Recent AchievementsNASDAQ:ACERAcer Therapeutics Inc
10/06/20229:01AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
10/06/20228:30AMGlobeNewswire Inc.Acer Therapeutics Announces University of North Carolina Receives Department of Defense Grant to Support the Proposed Investigator Sponsored OASIS Trial of ACER-801 (Osanetant) to Reduce the Frequency and Severity of Post-Traumatic Stress DisorderNASDAQ:ACERAcer Therapeutics Inc
10/05/20229:03AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
10/05/20228:30AMGlobeNewswire Inc.Acer Therapeutics Announces Expansion of ACER-801 (osanetant) Development Indications to Include Post-Traumatic Stress DisorderNASDAQ:ACERAcer Therapeutics Inc
10/03/20229:01AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
08/23/20228:31AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
08/23/20228:30AMGlobeNewswire Inc.Acer Therapeutics to Participate in August and September 2022 Investor ConferencesNASDAQ:ACERAcer Therapeutics Inc
08/22/202212:45PMTipRanksH.C. Wainwright Sticks to Its Buy Rating for Acer Therapeutics (ACER)NASDAQ:ACERAcer Therapeutics Inc
08/15/20225:05PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ACERAcer Therapeutics Inc
08/15/20224:19PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
08/15/20224:00PMGlobeNewswire Inc.Acer Therapeutics Reports Q2 2022 Financial Results and Provides Corporate UpdateNASDAQ:ACERAcer Therapeutics Inc
08/12/20229:01AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
08/12/20228:30AMGlobeNewswire Inc.Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine DiseaseNASDAQ:ACERAcer Therapeutics Inc
07/28/20229:02AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
07/28/20228:33AMGlobeNewswire Inc.Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine DiseaseNASDAQ:ACERAcer Therapeutics Inc
07/28/20228:30AMGlobeNewswire Inc.Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDsNASDAQ:ACERAcer Therapeutics Inc
07/18/20228:46AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
07/18/20228:30AMGlobeNewswire Inc.Acer Therapeutics Announces Resubmission of New Drug Application for ACER-001 for Treatment of UCDsNASDAQ:ACERAcer Therapeutics Inc
07/08/20228:30AMGlobeNewswire Inc.Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage FormNASDAQ:ACERAcer Therapeutics Inc
06/29/20229:04AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
06/27/20229:01AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
06/27/20228:30AMGlobeNewswire Inc.Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos SyndromeNASDAQ:ACERAcer Therapeutics Inc
06/22/20224:07PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ACERAcer Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ACER